| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
Revenue  | 2,269 | 2,291 | 2,286 | 2,300 | 2,310 | 2,232 | 2,360 | 2,266 | 2,479 | 2,127 | 3,165 | 3,206 | 3,197 | 2,870 | 2,875 | 3,547 | 3,658 | 3,429 | 3,271 | 3,555 | 3,672 | 3,462 | 3,663 | 3,645 | 3,551 | 3,971 | 6,106 | 3,590 | 3,821 | 3,989 | 3,993 | 4,199 | 4,890 | 5,089 | 4,313 | 4,403 | 5,526 | 6,110 | 5,182 | 5,181 |
| Expenses | 1,792 | 1,807 | 1,740 | 1,768 | 1,784 | 1,763 | 1,841 | 1,907 | 2,004 | 1,909 | 2,365 | 2,404 | 2,399 | 2,249 | 2,273 | 2,738 | 2,932 | 2,864 | 3,009 | 2,947 | 3,013 | 2,724 | 2,977 | 2,867 | 2,916 | 3,092 | 2,860 | 2,895 | 3,103 | 3,251 | 3,319 | 3,301 | 4,359 | 3,650 | 3,224 | 3,403 | 3,903 | 4,124 | 3,776 | 3,882 |
| EBITDA | 477 | 484 | 546 | 532 | 526 | 468 | 519 | 359 | 476 | 218 | 800 | 802 | 798 | 621 | 601 | 809 | 726 | 565 | 262 | 608 | 658 | 738 | 686 | 779 | 635 | 879 | 3,246 | 695 | 718 | 738 | 673 | 898 | 532 | 1,439 | 1,089 | 1,000 | 1,623 | 1,986 | 1,407 | 1,299 |
| Operating Profit % | 20 % | 20 % | 23 % | 22 % | 21 % | 20 % | 21 % | 15 % | 17 % | 9 % | 25 % | 24 % | 24 % | 19 % | 20 % | 22 % | 19 % | 16 % | 7 % | 17 % | 17 % | 20 % | 17 % | 20 % | 19 % | 21 % | 22 % | 18 % | 17 % | 17 % | 16 % | 21 % | 10 % | 28 % | 24 % | 22 % | 27 % | 32 % | 26 % | 24 % |
| Depreciation | 76 | 69 | 73 | 74 | 76 | 84 | 86 | 90 | 114 | 122 | 126 | 147 | 144 | 142 | 148 | 154 | 156 | 172 | 172 | 174 | 179 | 173 | 175 | 176 | 175 | 183 | 177 | 177 | 185 | 181 | 182 | 182 | 179 | 180 | 184 | 195 | 205 | 215 | 234 | 229 |
| Interest | 16 | 12 | 13 | 12 | 16 | 14 | 15 | 7 | 10 | 22 | 41 | 13 | 15 | 35 | 36 | 46 | 77 | 89 | 90 | 81 | 83 | 68 | 45 | 27 | 23 | 27 | 30 | 31 | 39 | 34 | 35 | 33 | 28 | 18 | 9 | 20 | 35 | 32 | 25 | 32 |
| Profit Before Tax | 426 | 519 | 545 | 537 | 498 | 441 | 435 | 324 | 412 | 154 | 712 | 722 | 724 | 570 | 535 | 672 | 606 | 394 | 122 | 457 | 522 | 588 | 524 | 617 | 526 | 777 | 3,135 | 598 | 558 | 673 | 648 | 781 | 484 | 1,328 | 1,006 | 947 | 1,550 | 1,900 | 1,271 | 1,184 |
| Tax | 69 | 51 | 60 | 97 | -74 | 36 | 46 | -6 | 20 | 9 | 200 | 168 | 125 | 102 | 107 | 150 | 124 | 69 | 28 | 86 | 108 | 102 | 89 | 89 | -210 | 135 | 123 | 87 | 105 | 96 | 122 | 149 | 125 | 195 | 203 | 157 | 304 | 417 | 351 | 158 |
| Net Profit | 357 | 468 | 485 | 440 | 572 | 405 | 389 | 331 | 393 | 145 | 513 | 553 | 599 | 467 | 428 | 522 | 482 | 325 | 94 | 371 | 414 | 487 | 435 | 528 | 735 | 643 | 3,012 | 511 | 453 | 576 | 526 | 631 | 358 | 1,134 | 803 | 790 | 1,246 | 1,483 | 920 | 1,026 |
| EPS in ₹ | 17.11 | 22.47 | 6.46 | 4.21 | 5.59 | 3.89 | 3.71 | 3.16 | 3.77 | 1.35 | 4.92 | 5.31 | 5.77 | 4.50 | 4.08 | 4.99 | 4.40 | 2.97 | 1.05 | 3.65 | 3.83 | 4.43 | 4.62 | 5.15 | 6.64 | 5.74 | 29.32 | 4.89 | 3.88 | 5.06 | 5.15 | 6.15 | 2.93 | 10.74 | 7.91 | 7.80 | 11.69 | 14.11 | 9.06 | 10.17 |
Zydus Life Science
926.70
+8.10
(0.88%)
Market Cap
93,247.70 Cr
EPS
38.14
PE Ratio
20.38
Dividend Yield
0.33 %
Industry
Healthcare52 Week High
1,324.30
52 Week Low
855.10
PB Ratio
4.23
Debt to Equity
0.05
Sector
Pharmaceuticals
Live Chart 
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from27 analysts
Company News
View All News
Zydus Lifesciences Receives FDA Approval for Apalutamide Tablets5 days ago
Zydus Lifesciences has received final approval from the U.S. Food and Drug Administration (FDA) for Apalutamide Tablets, 60 mg. The drug had annual sales of $1,099.8 million in the United States, according to IQVIA MAT data from January 2025.
Zydus Lifesciences: FDA Approves Manufacturing of Apalutamide Tablets5 days ago
Zydus Lifesciences received FDA approval to manufacture 60 mg Apalutamide tablets for treating metastatic castration-sensitive prostate cancer. The drug had annual US sales of $1.1 billion. Production will be at the Ahmedabad facility.
Zydus Lifesciences: FDA Approves Generic Prostate Cancer Drug5 days ago
Zydus Lifesciences received final FDA approval for apalutamide tablets, a generic version of Erleada, used to treat metastatic castration-sensitive prostate cancer. The drug had annual US sales of $1099.8 million as of January 2025. Zydus now has 420 FDA approvals.
View more
Peer Comparison Compare Peers on Screener
| Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
| 1,796.55 | 4,31,052.52 | 36.29 | 49,887.20 | 12.06 | 9,648 | 13.77 | 66.31 | |
| 5,813.85 | 1,54,339.45 | 74.44 | 8,184.00 | 0.89 | 1,600 | 64.53 | 54.14 | |
| 1,518.00 | 1,22,595.81 | 24.66 | 26,520.70 | 14.17 | 4,155 | 47.38 | 64.72 | |
| 3,221.30 | 1,09,023.43 | 58.60 | 10,785.70 | 11.59 | 1,656 | 13.54 | 61.48 | |
| 1,194.10 | 99,637.00 | 18.63 | 28,905.40 | 12.36 | 5,578 | 1.69 | 59.70 | |
| 2,341.05 | 96,583.97 | 48.83 | 10,615.60 | 19.57 | 1,942 | -16.38 | 57.94 | |
| 2,106.05 | 96,077.49 | 33.67 | 20,141.50 | 19.94 | 1,936 | 38.82 | 62.32 | |
| 926.70 | 93,247.70 | 20.38 | 19,831.50 | 13.82 | 3,831 | 29.92 | 52.97 | |
| 1,219.55 | 70,831.66 | 19.77 | 29,559.20 | 17.55 | 3,169 | -10.04 | 63.52 | |
| 30,340.15 | 64,470.70 | 48.19 | 6,097.20 | 10.80 | 1,201 | 16.01 | 54.89 |
Growth Rate
Revenue Growth
13.82 %
Net Income Growth
91.39 %
Cash Flow Change
20.05 %
ROE
70.50 %
ROCE
52.01 %
EBITDA Margin (Avg.)
23.08 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 9,047 | 10,551 | 15,221 | 18,065 | 23,483 | 23,687 | 23,885 | 27,795 | 25,756 | 29,281 |
| Fixed Assets | 3,352 | 3,748 | 5,755 | 6,483 | 12,164 | 12,231 | 12,133 | 12,189 | 11,521 | 12,369 |
| Current Assets | 4,227 | 4,280 | 6,022 | 8,230 | 8,498 | 8,715 | 8,716 | 12,095 | 10,008 | 11,420 |
| Capital Work in Progress | 798 | 951 | 1,543 | 1,527 | 837 | 742 | 783 | 726 | 1,201 | 2,423 |
| Investments | 121 | 416 | 435 | 746 | 674 | 765 | 830 | 3,288 | 1,547 | 1,221 |
| Other Assets | 4,776 | 5,436 | 7,488 | 9,310 | 9,809 | 9,950 | 10,139 | 11,593 | 11,488 | 13,269 |
| Total Liabilities | 9,047 | 10,551 | 15,221 | 18,065 | 23,483 | 23,687 | 23,885 | 27,795 | 25,756 | 29,281 |
| Current Liabilities | 3,285 | 3,461 | 5,306 | 6,083 | 7,343 | 8,269 | 7,861 | 7,827 | 5,527 | 5,340 |
| Non Current Liabilities | 1,342 | 1,255 | 2,799 | 3,047 | 4,461 | 3,707 | 1,094 | 915 | 541 | 1,840 |
| Total Equity | 4,421 | 5,835 | 7,116 | 8,936 | 11,679 | 11,710 | 14,930 | 19,054 | 19,688 | 22,102 |
| Reserve & Surplus | 4,149 | 5,597 | 6,858 | 8,642 | 10,284 | 10,273 | 12,890 | 16,897 | 17,415 | 19,729 |
| Share Capital | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 101 | 101 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 178 | 99 | 756 | -3 | -811 | 399 | -91 | 219 | -170 | -75 |
| Investing Activities | -465 | -860 | -2,872 | -974 | -3,977 | -1,004 | -837 | -1,018 | 1,542 | -1,492 |
| Operating Activities | 994 | 1,894 | 1,312 | 919 | 1,282 | 2,932 | 3,294 | 2,105 | 2,689 | 3,228 |
| Financing Activities | -351 | -935 | 2,316 | 52 | 1,885 | -1,528 | -2,548 | -868 | -4,400 | -1,810 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
| Promoter | 74.88 % | 74.88 % | 74.88 % | 74.88 % | 74.88 % | 74.88 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 5.72 % | 5.59 % | 7.52 % | 7.53 % |
| DIIs | 11.11 % | 10.43 % | 11.22 % | 11.78 % | 12.78 % | 11.92 % | 12.94 % | 13.69 % | 13.60 % | 13.23 % | 13.09 % | 12.79 % | 12.63 % | 12.64 % | 10.65 % | 10.65 % |
| Government | 0.19 % | 0.07 % | 0.07 % | 0.07 % | 0.08 % | 0.08 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 6.16 % | 7.31 % | 7.38 % | 7.40 % | 7.81 % | 8.02 % | 7.60 % | 7.04 % | 6.42 % | 5.97 % | 5.67 % | 5.60 % | 5.29 % | 5.37 % | 5.48 % | 5.47 % |
| Others | 7.66 % | 7.32 % | 6.44 % | 5.87 % | 4.46 % | 5.11 % | 4.48 % | 4.29 % | 5.00 % | 5.82 % | 6.26 % | 6.63 % | 1.38 % | 1.43 % | 1.37 % | 1.36 % |
| No of Share Holders | 0 | 2,23,384 | 3,31,155 | 3,51,595 | 3,70,931 | 4,08,017 | 4,55,624 | 4,08,231 | 3,70,396 | 3,11,764 | 2,97,953 | 3,06,495 | 2,94,324 | 3,36,309 | 3,70,863 | 3,65,356 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 3.2 | 3.5 | 3.5 | 3.5 | 3.5 | 2.5 | 6 | 3 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.85 | 1.01 | 1.31 | 0.79 | 1 | 0.51 | 0.6 | 0.33 | 0.00 |
Corporate Action
Login to View
This information is available only for users of ScanX and Dhan.To proceed ahead,
LoginOpen Account
Announcements
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Newspaper Publication
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Investor Presentation
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Acquisition
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Newspaper Publication
Revised ESG Score
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Demand Notice Received By Zydus Healthcare Limited A Wholly Owned Subsidiary Company From GST Department
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Announcement under Regulation 30 (LODR)-Change in Management
Announcement under Regulation 30 (LODR)-Newspaper Publication
Intimation Of ESG Rating
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Integrated Filing (Financial)
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Investor Presentation
Board Meeting Outcome for Unaudited Financial Results For The Quarter / Nine Months Ended On December 31 2024
Unaudited Financial Results For The Quarter / Nine Months Ended On December 31 2024
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Newspaper Publication
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Demand Notice By GST Department
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Demand Notice By GST Department
Board Meeting Intimation for Approval Of Unaudited Financial Results Of The Company For The Quarter / Nine Months Ended On December 31 2024
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Announcement under Regulation 30 (LODR)-Newspaper Publication
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Change in Management
Announcement under Regulation 30 (LODR)-Credit Rating
Technical Indicators
RSI(14)
Neutral 52.97
ATR(14)
Less Volatile 23.34
STOCH(9,6)
Neutral 61.28
STOCH RSI(14)
Overbought 100.00
MACD(12,26)
Bullish 6.11
ADX(14)
Weak Trend 19.95
UO(9)
Bearish 46.51
ROC(12)
Uptrend And Accelerating 5.39
WillR(14)
Overbought -16.17
About Zydus Life Science
Zydus Lifesciences Limited is an Indian global life sciences company that discovers, develops, manufactures, and markets healthcare therapies. Its product portfolio includes active pharmaceutical ingredients, human formulations, animal health products, and wellness products. The company operates in pharmaceuticals, covering human and veterinary formulations, bulk drugs, diagnostics, herbal products, skin care, and over-the-counter products. Zydus has a global presence, marketing products in the United States, India, Europe, and emerging markets. Key products include Lipaglyn, Bilypsa, Ujvira, Exemptia, Vivitra, and Bryxta, covering areas such as oncology, autoimmune diseases, nephrology, and infectious illnesses. The company has manufacturing facilities in various Indian states and has made several strategic acquisitions and partnerships to expand its product range and market presence.
Listing Date
27 Apr, 2000(24 Years,
25 days)
Website
Chairperson NamePankaj R Patel
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
